APA-referens

Kaseb, A. O., Morris, J. S., Iwasaki, M., Al-Shamsi, H. O., Raghav, K. P. S., Girard, L., . . . Yao, J. C. (2016). Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther.

Chicago-stil citat

Kaseb, Ahmed O., et al. "Phase II Trial of Bevacizumab and Erlotinib As a Second-line Therapy for Advanced Hepatocellular Carcinoma." Onco Targets Ther 2016.

MLA-referens

Kaseb, Ahmed O., et al. "Phase II Trial of Bevacizumab and Erlotinib As a Second-line Therapy for Advanced Hepatocellular Carcinoma." Onco Targets Ther 2016.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.